anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is based in part upon the discovery that the use of pyruvate in enteral formulations, in combination with an anabolic protein composition, produces a synergistic effect in increasing the lean body mass or muscle tissue of a mammal consuming same. The present invention also provides a method for enhanced endurance of athletes. The present invention relates generally to a composition for enhancing the protein concentration or muscle mass of a mammal and a method for enhancing the protein concentration or muscle mass in a mammal. More specifically, the present invention relates to a composition which comprises pyruvate and/or derivatives of pyruvate and an anabolic protein composition. The method of the present invention comprises administering to a mammal in need of enhancing its protein concentration or muscle mass, a composition comprising pyruvate and an anabolic protein composition. The pyruvate/anabolic protein composition can take the form of powders, liquids, pills, capsules, tablets, food additives, candies or confections.
A method is provided for clinical retention of restorative material by a natural tooth. A first portion of photopolymerizable liquid primer/adhesive dental composition is applied to a tooth surface. After leaving the first portion of the liquid composition on the tooth surface undisturbed for at least 15 seconds on the tooth surface air is conveyed against the first portion of the liquid. The light is impinged on the first portion of the liquid composition whereby at least a portion of the first portion of the liquid composition polymerizes to form a first coating on the tooth. A second portion of the liquid composition is applied to the first coating, and air is substantially immediately conveyed to the second portion of the liquid composition. Light is then impinged on the first and second portions of the liquid composition whereby at least a portion of the second portion of the composition polymerizes to form a polymeric material on a treated tooth surface adapted to retain a restorative material at a clinical retention rate of at least 98 percent with acceptable marginal integrity. The polymeric material has a yield strength of at least 50 MPa, an elastic modulus of at least 1,000 MPa, a resilience of at least 0.4 MPa and/or provides an initial marginal integrity after etching of at least 90 percent.
BACKGROUND: Management of mediastinal anastomotic leaks (MALs) after Ivor Lewis esophagectomy includes conservative, endoscopic, or surgical management. Endoscopic vacuum therapy (EVAC) is becoming a routine approach for MALs, although the outcomes have not been defined. This study aimed to describe the incidence, treatment, and outcomes of MALs in patients who underwent esophagectomy in 3 Italian high-volume centers that routinely use EVAC for MAL.
METHODS: Patients who underwent Ivor Lewis esophagectomy between September 2018 and March 2023 were included.
RESULTS: A total of 681 patients underwent Ivor Lewis esophagectomy, of whom 88 had MAL. The MAL rates for open, minimally invasive, and robotic esophagectomies were 11.5%, 13.4%, and 14.8%, respectively. Global and specific 30- and 90-day mortality rates for MAL were 0.9% and 2.1% and 6.8% and 15.9%, respectively. Nonoperative management (NOM) as the primary treatment was chosen for 62 patients. EVAC was the most common NOM (62.9%), and the most common operative management (OM) was anastomotic redo (53.8%). Diversion was the OM for 7 patients, of whom 3 patients died. Primary treatment proved successful in 40 patients. Among them, EVAC alone was successful in 35.9% of patients. Globally, endoscopic treatment, including EVAC, was successful in 79.0% of NOM and 55.7% of MALs. NOM and OM were chosen as secondary treatments for 27 and 10 patients, respectively. Secondary treatment proved successful in 21 patients.
CONCLUSION: The incidence of MALs after Ivor Lewis esophagectomy is approximately 13%. Endoscopic techniques have a success rate of almost 80%, with EVAC representing a significant part of this treatment process.
OBJECTIVES: To explore the effectiveness of tofacitinib for immunoglobulin G4-related disease (IgG4-RD) and idiopathic retroperitoneal fibrosis (IRF), and investigate the expression of JAKs in the lesion of these diseases.
METHODS: Clinical data of patients with IgG4-RD or IRF who were administered with tofacitinib monotherapy were collected. IgG4-RD responder index (IgG4-RD RI) was assessed. The expression of JAK1, JAK2, JAK3, and TYK2 were analysed with immunohistochemistry staining in three salivary glands specimens of IgG4-RD and one retroperitoneal tissue of IRF.
RESULTS: Two patients with IRF and two patients with IgG4-RD used tofacitinib monotherapy. Two patients with IRF achieved complete remission with diminished retroperitoneal mass and decreased CRP, as IgG4-RD RI decreased from 6 to 1 in both of them. One with IgG4-RD achieved complete remission with alleviated enlargement of pancreas and IgG4 level decreased from 13.7 g/L to 2.4 g/L, as IgG4-RD RI decreased from 12 to 1. One with IgG4-RD achieved partial response with IgG4 level decreased from 77.1g/L to 25.8g/L as IgG4-RD RI from 18 to 6. JAK1, JAK2, JAK3, and TYK2 expression were detected in biopsy tissues. The staining intensity of the JAK family on the lesion from one IRF patient was similar to those from IgG4-RD patients.
CONCLUSIONS: Tofacitinib is a potentially effective treatment for IgG4-RD and IRF and it is reasonable to conduct clinical trial to validate its efficacy. The JAKs were expressed in the inflammatory lesions of IgG4-RD and IRF and they may share a common pathogenesis pathway that is independent of IgG4 production.
Safety and effectiveness of BENLYSTA have been established for the treatment of SLE and lupus nephritis in pediatric patients 5 to less than 18 years of age.

Intravenous Use

Use of BENLYSTA intravenously in pediatric patients with SLE is supported by evidence from pharmacokinetic (PK) and efficacy results from a pediatric study (Trial 6), as well as PK exposure and extrapolation of the established efficacy of BENYLSTA plus standard therapy from the Phase 3 intravenous studies in adults with SLE. A randomized, double‑blind, placebo‑controlled, PK, efficacy, and safety study (Trial 6) to evaluate intravenously administered BENLYSTA 10 mg/kg plus standard therapy compared with placebo plus standard therapy over 52 weeks was conducted in 93 pediatric patients with SLE. The proportion of pediatric patients achieving an SRI-4 response was higher in patients receiving BENLYSTA plus standard therapy compared with placebo plus standard therapy. Pediatric patients receiving BENLYSTA plus standard therapy also had a lower risk of experiencing a severe flare compared with placebo plus standard therapy [see Clinical Studies (14.3)]. Pharmacokinetics were evaluated in a total of 53 pediatric patients with SLE and were consistent with the adult population with SLE [see Clinical Pharmacology (12.3)].

Use of intravenous administration of BENLYSTA in pediatric patients with active lupus nephritis is based on the extrapolation of efficacy from the intravenous study in adults (n = 224) with active lupus nephritis, and supported by pharmacokinetic data from intravenous studies in adults (n = 224) with active lupus nephritis and from pediatric patients (n = 53) with SLE. Estimated belimumab exposures for pediatric patients were comparable to adults with active lupus nephritis [see Clinical Pharmacology (12.3)].

Subcutaneous Use

Use of BENLYSTA, administered subcutaneously in pediatric patients (5 to less than 18 years of age and weighing at least 15 kg) with SLE, is supported by evidence from an open-label pharmacokinetic trial (subcutaneous administration of BENLYSTA in pediatric patients with SLE) and Trial 6 (a pharmacokinetic, efficacy, and safety study of intravenous dosing in pediatric patients with SLE). The pharmacokinetics of belimumab, following subcutaneous administration in pediatric patients, are estimated to be similar to adults who receive BENLYSTA subcutaneously and pediatric patients who receive BENLYSTA intravenously [see Clinical Pharmacology (12.3)].

The safety and effectiveness of the subcutaneous administration of BENLYSTA, in pediatric patients less than 18 years of age with active lupus nephritis, have not been established. The safety and effectiveness of BENLYSTA have not been established in pediatric patients less than 5 years of age.
Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
<P>PROBLEM TO BE SOLVED: To provide a method to therapeutically modulate immune functions of autoimmune diseases and other disorders in immune systems in a mammal.  <P>SOLUTION: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell (e.g., an antigen-presenting cell) is disclosed. Such inhibition is useful for treatment of diseases including the various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-gamma by lymphocytes or other immune cells in the mammal. Inhibition of IFN-gamma is useful for treatment of inflammatory diseases or disorders (e.g., inflammatory bowel disease).  <P>COPYRIGHT: (C)2011,JPO&INPIT
Biomarkers are not broadly used in the management of head and neck cancers (HNCs). Biomarkers have been beneficial in the management of other cancers, however, not in HNCs. Therefore, we observed the immunopositivity of a novel biomarker called immunoglobulin superfamily member 3 (IGSF3) in tumor tissues in HPV-related and HPV-unrelated OPSCC. Two patient cohorts (C1 and C2) from separate time periods were available for this study (total N = 282). Both consisted of OPSCC patients treated at the Helsinki University Hospital (HUS, Helsinki, Finland) during 2000-2016. For HPV determination, HPV mRNA in situ hybridization was used. Immunohistochemistry was used to assess IGSF3 immunopositivity in cancer tissues. Overall survival (OS) was used as endpoint in the statistical analysis. In C1, stronger immunopositivity of IGSF3 in tumor-infiltrating lymphocytes (TILs) correlated with favorable OS (p = 0.005). Stronger IGSF3 immunopositivity in tumor cells (TCs) was associated with HPV negativity (p = 0.017). Stronger IGSF3 immunopositivity in TILs correlated with HPV positivity (p < 0.001). Elevated IGSF3 immunopositivity in TILs associates with HPV-related tumors and may signify favorable prognosis. The immunopositivity of IGSF3 differs between HPV-related and HPV-unrelated OPSCC.
Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
Method: Family Physicians included a random sample of multimorbid patients who attended appointments in their offices from July to December 2014. Inclusion criteria were those of the EGPRN definition of Multimorbidity. Exclusion criteria were patients under legal protection and those unable to complete the 2-year follow-up. Decompensation was defined as the occurrence of death or hospitalization for more than seven days. Statistical analysis was undertaken with uni- and multivariate analysis at a 6-month follow-up using a combination of approaches including both automatic classification and expert decision making. A Multiple Correspondence Analysis (MCA) confirmed results consistency and completed the process with a projection of illustrative variables. A logistic regression was finally performed in order to identify and quantify risk factors for decompensation.
Disclosed is an infusion pump for expelling a fluid from a collapsible fluid reservoir to a patient. The pump includes a housing having a chamber therein for receiving the fluid reservoir. A first wall is provided on the housing for contacting the fluid reservoir, and a second wall is movable from a first position distanced from the first wall to form the chamber therebetween, and a second position relatively closer to the first wall. Advancing the movable wall from the first position to the second position expels fluid from the collapsible reservoir at a substantially constant rate by applying increasing force on the fluid reservoir through the dispensation cycle. Preferably, the first and second walls are provided with non-planar complementary surface configurations for contacting the collapsible reservoir. Retraction mechanisms for retracting the movable wall from the second position to the first position, and user readable indicium of the status of the dispensation cycle are also disclosed.
Microspheres for releasing an octreotide compound without an initial time lag include a poly(D,L-lactide-co-glycolide) polymer (PLGA polymer) matrix having a ratio of lactide to glycolide ranging from 80:20 to 90:10 mol %. The polymer has a molecular weight ranging from about 6000 to 16000. The octreotide compound is dispersed in the polymer matrix. The microspheres can be made by forming a dispersed phase by combining the above polymer, dichloromethane, the octreotide compound, methanol and acetic acid. A target loading of the octreotide compound in the dispersed phase ranges from 7 to 12% by weight. Polyvinyl alcohol is dissolved in water to form a continuous phase. The dispersed phase is mixed in the continuous phase to form a microsphere suspension. The dichloromethane, acetic acid, methanol and polyvinyl alcohol are removed from the microsphere suspension. Residual dichloromethane and methanol are removed from the microspheres by washing.
Pregnancy-related death (PRD) rates have risen 120-200% in the United States in the past two decades, and experts estimate that 40-60% of these cases are preventable. Improvement initiatives are predominantly hospital-based and rely on perinatal people recognizing their own symptoms and seeking care without ample support or education. We hypothesize that we can improve patients' self-efficacy and decision-making about when to seek care by helping them to self-monitor symptoms and by providing decision support. We propose to develop a mHealth-based, patient-reported outcome (PRO) and decision-support system to help mothers determine when to seek care for warning signs of PRD. Our project focuses on diverse populations facing postpartum disparities, particularly African- American and Spanish-speaking Latina women. This protocol involves a single-arm pilot trial assessing the feasibility and preliminary effectiveness of MOMS/MAMA for improving knowledge and patient activation among postpartum patients.
Most of the opioids used are centrally acting drugs like morphine or its derivatives. The most common adverse reactions related to systemic administration of opioids are sedation, itching, constipation and less commonly, respiratory depression. One of the other management strategies for the pain control is the use of non-steroidal anti-inflammatory drugs (NSAIDS). Frequent use of NSAIDS is also associated with complications, such as gastric ulcer and platelet dysfunction. When compared to other non-NSAIDS, IV acetaminophen is a relatively safer drug with quicker onset of action. In an earlier conducted study, the onset of action of analgesia for a bolus dose of IV acetaminophen is 3 minutes. IV acetaminophen is FDA approved for management of mild to moderate pain. An adverse reaction associated with the prolonged usage of IV acetaminophen is hepatic injury. The most common adverse events encountered during previous clinical trials were nausea, vomiting, headache and insomnia.
PURPOSE: To wash and disinfect a contact lens simultaneously by contacting the contact lens with an aqueous system containing an antibacterial agent and a proteolytic enzyme for a sufficient time. CONSTITUTION: This composition used for washing and disinfection of a contact lens, consists of water, one or more proteolytic enzyme(s) and one or more antibacterial agent(s). The proteolytic enzyme has an ability to hydrolyze peptide-amide bonds at least partly and cut a proteinaceous material into a small water-soluble subunit. Other lipase or carbohydrase may be used in combination with it. Furthermore, a disinfectant is not precipitated in the presence of the enzyme and contains a disinfecting amount of one or more antibacterial agent(s) suitable for the enzyme. The disinfecting amount means an amount to decrease a microbial group at least partly in the used pharmaceuticals, preferably to decrease a microbial loading amount within 4 hours for 2 log orders, and within 1 hour for 1 log order.
The present invention discloses a method for preparing a medicine for treating rheum. Paracetanol, balloonflower root, forsythia suspensa, prepared soybean, liquorice, lophatherum gracile, honeysuckle flower, fructus arctii, schizonepeta spike and menthol are taken as raw materials. The ten components are prepared by the following steps: respectively crushing paracetanol and balloonflower root to fine powder; extracting volatile oil from schizonepeta spike, dissolving schizonepeta spike oil and menthol are dissolved with appropriate ethanol; adding water into the other six components and decocting for two times, filtering, combining the filter liquors, condensing the filter liquor, adding balloonflower root, paracetamol powder and supplementary material, spray drying, adding schizonepeta spike oil and menthol ethanol solution, mixing to uniform, and compressing to tablet for obtaining the product. The total powder are directly compressed to tablet, and the procedures of granulating, drying, etc. are saved. The method saves time and energy. The method can save cost of 500 thousand yuan per year and brings considerable economic benefit for the enterprise.
In a vehicle-controlled study for the treatment of psoriasis of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the drug vehicle had excellent to cleared clinical response.

Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients, were treated with Derma-Smoothe/FS® twice daily for 4 weeks. Morning pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 ug/dL; normal: cortisol > 7 ug/dL) but all had normal responses to 0.25 mg of Cortrosyn stimulation (cortisol > 18 ug/dL).

A clinical study was conducted to assess the safety of Derma-Smoothe/FS®, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 patients with atopic dermatitis, 6 to 17 years of age. Of the 13 patients, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the responses to both prick test and patch test utilizing refined peanut oil NF, Derma-Smoothe/FS® and histamine/saline controls, on the 13 individuals. These subjects were also treated with Derma-Smoothe/FS® twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to Derma-Smoothe/FS® and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of Derma-Smoothe/FS® use. Importantly, the bulk peanut oil NF, used in Derma-Smoothe/FS® is heated at 475° F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins.
A composition for preventing or treating diabetes mellitus comprising Lactobacillus gasseri BNR17 is provided to show excellent blood glucose lowering effect and improve polyphagia, polydipsia and polyuria excellently. A food composition for preventing or treating diabetes mellitus comprises Lactobacillus gasseri BNR17(deposition no. KCTC 10902BP) as an effective ingredient and is prepared by adding an effective amount of the Lactobacillus gasseri to a food. A pharmaceutical composition for preventing or treating diabetes mellitus comprises an effective amount of the Lactobacillus gasseri BNR17(deposition no. KCTC 10902BP) and a pharmaceutically acceptable carrier and is prepared by mixing the effective amount of the Lactobacillus gasseri BNR17 with the carrier. Further, the food composition is food or an additive for food.
The purpose of this study will be to investigate the effects of whey protein vs. leucine-matched collagen supplementation on muscle mass and function after a 10-wk resistance training program. Initially, all participants will be submitted for a 2-wk familiarization period, and then randomized into two groups (N = 11 / group): whey protein group and leucine-matched collagen group. The following variables will be assessed from pre-to post-training: anthropometric, muscle thickness from vastus lateralis and biceps brachii muscles using ultrasound, training load, mean power and peak torque for unilateral arm flexion exercise using a isokinetic dynamometer, countermovement vertical jump, nutritional intake, and testosterone-to-cortisol ratio . Shapiro-Wilk and Levine tests will be used to test the normality and homogeneity of the measurements, respectively. Two-way ANOVA (group x time) tests for repeated measures will be performed to assess changes over time and between groups for all dependent variables. Violation of sphericity will adjust using Greenhouse- Geyser correction. The Bonferroni post-hoc test will detect specific differences between groups. When appropriate, the percentage of change (∆%) will be reported according to the following equation: ∆% = \[(pre-average post average) / pre-average mean\] × 100. Values will be express as mean ± standard deviation. O significance level α will be 0.05.
In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from V beta  to J beta  of the V beta 13.1 gene in V beta 13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the V beta 13.1 gene pair, to amplify a portion of the V beta 13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of V beta 13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored. The autoimmune disease can be treated by administering a peptide comprising the LGRAGLTY motif.